Knight Therapeutics Seeks Brazilian Approval for NIKTIMVO® in Chronic GVHD
Event summary
- Knight Therapeutics' Brazilian affiliate submitted a marketing authorization application for NIKTIMVO® (axatilimab) to ANVISA for treating chronic GVHD.
- The submission follows Knight's expanded agreement with Incyte for exclusive distribution rights in Latin America.
- NIKTIMVO® received U.S. FDA approval in August 2024 for chronic GVHD after failure of at least two prior lines of systemic therapy.
- Chronic GVHD affects 30%-70% of allogeneic stem cell transplant recipients globally, with a 2-year cumulative incidence of 29.5% in Brazil.
The big picture
Knight Therapeutics is leveraging its partnership with Incyte to expand access to NIKTIMVO® in Latin America, a region with significant unmet needs in chronic GVHD treatment. The submission in Brazil follows a strategic deal to distribute multiple Incyte products, positioning Knight as a key player in the regional specialty pharmaceutical market. The success of this submission could set a precedent for future regulatory approvals in the region.
What we're watching
- Regulatory Timing
- The pace at which ANVISA reviews the submission will determine NIKTIMVO's market entry in Brazil.
- Commercial Execution
- Whether Knight can effectively distribute NIKTIMVO alongside other Incyte products in Latin America.
- Clinical Expansion
- How ongoing trials for axatilimab in other indications may impact its long-term value.
Related topics